Related Experiment Video
Updated: Jan 7, 2026
10:37
Transcranial Direct Current Stimulation tDCS for Memory Enhancement
Published on: September 18, 2021
15.4K
Dementia Care Research and Psychosocial Factors
Emily E Munn1, Anna Montelongo2, Viraj K Patel2
1Indiana University Bloomington, Bloomington, IN, USA.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
Summary
Interventions for Alzheimer's disease (AD) show promise for individuals with Down syndrome (DS). Pharmacological, exercise, and cognitive training approaches can improve cognitive and behavioral outcomes in this population.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Down syndrome (DS) is a significant genetic risk factor for Alzheimer's disease (AD).
- AD symptom incidence rises sharply in DS individuals aged 40-54, from 8% to 80%.
- Limited research exists on AD prevention and treatment specifically for individuals with DS.
Purpose of the Study:
- To systematically review and meta-analyze the efficacy of interventions for preventing and treating AD in individuals with DS.
- To evaluate both pharmacological and non-pharmacological interventions.
Main Methods:
- Systematic review and meta-analysis of English, peer-reviewed articles published up to December 1st, 2023.
- Included studies focused on adults aged 18-69 with DS and AD-related cognitive/behavioral outcomes.
- Screened 781 records, with 25 articles (1,417 participants) meeting inclusion criteria.
Main Results:
- Four intervention types were analyzed: pharmacological (18 studies), exercise (5), environmental (1), and cognitive training (1).
- Overall, interventions significantly improved cognitive and behavioral outcomes (p < 0.0001).
- High heterogeneity was observed among the intervention effects (I² = 93.8%).
Conclusions:
- Interventions demonstrate effectiveness for AD in individuals with DS.
- Specific pharmacological agents (donepezil, antidepressants, EGCG, simvastatin, nicotine) show broad benefits.
- Exercise and cognitive training present promising strategies for reducing AD symptoms in this population.
More Related Videos
08:36The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
4.3K
10:13Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
Published on: February 14, 2014
14.1K
Related Concept Videos
01:30Dementia
482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
482
01:29Psychological and Sociocultural Causes of Schizophrenia
438
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
438
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
01:30Cognitive Development During Adulthood
740
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
740
01:29Documentation in Long-Term and Home Healthcare Setting
1.4K
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
1.4K